Label: LOVAZA- omega-3-acid ethyl esters capsule

  • NDC Code(s): 80725-420-12
  • Packager: Waylis Therapeutics LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated February 5, 2025

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use LOVAZA safely and effectively. See full prescribing information for LOVAZA. LOVAZA (omega-3-acid ethyl esters capsules), for oral ...
  • Table of Contents
    Table of Contents
  • 1 INDICATIONS AND USAGE
    LOVAZA (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg/dL ...
  • 2 DOSAGE AND ADMINISTRATION
    Assess TG levels carefully before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, medications) of high TG levels and manage as appropriate [see Indications and ...
  • 3 DOSAGE FORMS AND STRENGTHS
    LOVAZA (omega-3-acid ethyl esters) capsules are supplied as 1-gram transparent, soft-gelatin capsules filled with light-yellow oil and bearing the designation "LOVAZA".
  • 4 CONTRAINDICATIONS
    LOVAZA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to LOVAZA or any of its components.
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Monitoring: Laboratory Tests - In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy ...
  • 6 ADVERSE REACTIONS
    6.1 Clinical Trials Experience - Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly ...
  • 7 DRUG INTERACTIONS
    7.1 Anticoagulants or Other Drugs Affecting Coagulation - Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - Risk Summary - The available data from published case reports and the pharmacovigilance database on the use of LOVAZA in pregnant women are insufficient to identify a ...
  • 11 DESCRIPTION
    LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - The mechanism of action of LOVAZA is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - In a rat carcinogenicity study with oral gavage doses of 100, 600, and 2,000 mg/kg/day, males were treated with omega-3-acid ethyl ...
  • 14 CLINICAL STUDIES
    14.1 Severe Hypertriglyceridemia - The effects of LOVAZA 4 grams per day were assessed in 2 randomized, placebo-controlled, double-blind, parallel-group trials of 84 adult subjects (42 on LOVAZA ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    LOVAZA (omega-3-acid ethyl esters) capsules are supplied as 1-gram, transparent, soft-gelatin capsules filled with light-yellow oil and bearing the designation "LOVAZA". Bottles of 120: NDC ...
  • 17 PATIENT COUNSELING INFORMATION
    Advise the patient to read the FDA-approved patient labeling (Patient Information). Information for Patients - LOVAZA should be used with caution in patients with known sensitivity or allergy ...
  • SPL UNCLASSIFIED SECTION
    Manufactured for: Waylis Therapeutics LLC - Rahway, NJ 07065
  • PATIENT PACKAGE INSERT
    PATIENT INFORMATION - LOVAZA (LO-VA-ZA) (omega-3-acid ethyl esters - capsules) This Patient Information has been approved by the U.S. Food and Drug Administration.Revised 11/2024 - What is ...
  • PRINCIPAL DISPLAY PANEL - 1 gram Bottle Label
    NDC 80725-420-12 - Lovaza® (omega-3-acid - ethyl esters) Capsules - 1 gram* Swallow capsules whole. Rx only - 120 Capsules - Waylis - THERAPEUTICS
  • INGREDIENTS AND APPEARANCE
    Product Information